page_title: Nintedanib
section_title: Chemistry
hierarchical_section_title: Nintedanib / Chemistry
context_page_description: Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
  In March 2020, it was approved for use in the United States to treat chronic fibrosing interstitial lung diseases with a progressive phenotype. It is the first treatment for this group of fibrosing lung diseases that worsen over time that was approved by the U.S. Food and Drug Administration.
  Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.
  Ofev was developed by Boehringer Ingelheim. It received U.S. Food and Drug Administration approval for use for idiopathic pulmonary fibrosis in 2014 - one of only two drugs available for treating IPF - and numerous studies since have demonstrated its effectiveness in slowing the progressive, terminal lung disease.
context_section_description: The drug is used in form of its salt with ethanesulfonic acid. This salt, nintedanib esilate, is a yellow, crystalline solid that melts at 244 °C (471 °F) to 251 °C (484 °F). It has poor solubility in water, and somewhat better solubility in dimethyl sulfoxide at 25 g/l.
caption: Ethanesulfonic acid
exif: {}